NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.07. At the close of trading, the stock’s price was $18.35, to imply an increase of 1.55% or $0.28 in intraday trading. The NAMS share’s 52-week high remains $26.35, putting it -43.6% down since that peak but still an impressive 51.5% since price per share fell to its 52-week low of $8.90. The company has a valuation of $1.70B, with an average of 0.65 million shares in intraday trading volume over the past 10 days and average of 427.47K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for NewAmsterdam Pharma Company NV (NAMS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give NAMS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
After registering a 1.55% upside in the last session, NewAmsterdam Pharma Company NV (NAMS) has traded red over the past five days. The 5-day price performance for the stock is -7.56%, and -15.75% over 30 days. With these gigs, the year-to-date price performance is 64.28%. Short interest in NewAmsterdam Pharma Company NV (NASDAQ:NAMS) saw shorts transact 1.01 million shares and set a 2.62 days time to cover.
The extremes give us $36 and $45 for target low and target high price respectively. As such, NAMS has been trading -145.23% off suggested target high and -96.19% from its likely low.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
Looking at statistics comparing NewAmsterdam Pharma Company NV share performance against respective industry, we note that the company has underperformed competitors. NewAmsterdam Pharma Company NV (NAMS) shares are -4.92% down over the last 6 months, with its year-to-date growth rate lower than industry average at 3.72% against 16.60%.
NAMS Dividends
NewAmsterdam Pharma Company NV has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
NewAmsterdam Pharma Company NV insiders hold 0.25% of total outstanding shares, with institutional holders owning 89.59% of the shares at 89.82% float percentage. In total, 89.59% institutions holds shares in the company.
